This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Medivation | |
|---|---|
| Name | Medivation |
| Industry | Biotechnology |
| Fate | Acquired by Pfizer |
| Founded | 1999 |
| Founder | Peter G. Paul |
| Headquarters | San Francisco, California |
| Key people | David Hung, Steven Kortanek |
| Products | Enzalutamide (Xtandi) |
| Revenue | See Financial performance |
Medivation Medivation was a biopharmaceutical company focused on oncology therapeutics, notable for developing androgen receptor inhibitors and attracting industry attention through strategic partnerships and acquisition activity. The company interacted with major pharmaceutical firms, venture capital investors, regulatory agencies, and academic collaborators while advancing clinical-stage programs for prostate cancer and CNS indications. Medivation's trajectory involved landmark clinical trials, high-profile management, and a multi-billion dollar acquisition that influenced cancer drug development and corporate consolidation in the biotechnology sector.
Medivation was founded in 1999 by entrepreneur Peter G. Paul and built its early pipeline through collaborations with institutions such as University of California, San Francisco, Memorial Sloan Kettering Cancer Center, and venture investors including Abingworth and Accel Partners. The company advanced programs through preclinical and early clinical stages alongside alliances with pharmaceutical firms like Astellas Pharma and engaged with regulatory bodies including the Food and Drug Administration and the European Medicines Agency. Over its timeline Medivation faced competition and benchmarking against programs from companies such as Johnson & Johnson, Roche, Novartis, and AstraZeneca while participating in industry conferences like the American Society of Clinical Oncology and engaging with guideline committees such as the National Comprehensive Cancer Network.
Medivation's corporate governance featured a board of directors with members from investment firms such as Perceptive Advisors and biopharma executives formerly of Genentech, Pfizer, and Gilead Sciences. Executive leadership included founders and CEOs who interacted with corporate development teams from companies like Eli Lilly and Company, Bristol-Myers Squibb, and strategic advisers from Goldman Sachs and J.P. Morgan. Human resources, legal counsel, and medical affairs coordinated with clinical operations groups experienced with partners such as ICON plc and Parexel while investor relations maintained communications with institutional shareholders including BlackRock and Vanguard Group.
Medivation's R&D centered on small-molecule inhibitors and CNS-targeted programs developed with academic collaborators like Dana-Farber Cancer Institute and research institutes such as The Scripps Research Institute. Preclinical studies leveraged models and technologies from centers like Jackson Laboratory and imaging partnerships with firms including GE Healthcare and Siemens Healthineers. Clinical-stage programs were designed alongside contract research organizations such as Quintiles and bioanalytical vendors like LabCorp while engaging with regulatory science experts from MIT and Harvard Medical School for translational biomarker development.
Medivation's lead product was an androgen receptor signaling inhibitor approved for metastatic castration-resistant prostate cancer and evaluated in randomized trials reported at meetings such as European Society for Medical Oncology and American Urological Association. Phase II and Phase III programs compared outcomes against standards of care practiced at centers like Mayo Clinic and Cleveland Clinic and measured endpoints consistent with protocols from SWOG and EORTC. Trials involved collaborations with cooperative groups including NCI-designated centers and were monitored by data safety committees with members from Johns Hopkins University, UCLA, and University of Pennsylvania. Investigational pipelines included compounds targeted to neurology indications with preclinical partnerships with academic labs at Stanford University and translational studies referenced by investigators from Columbia University.
Medivation pursued private financings with investors such as Kleiner Perkins and public offerings coordinated by investment banks including Morgan Stanley and Goldman Sachs. The company's market capitalization and revenue streams were compared to peers like Amgen and Biogen and influenced M&A activity involving bidders including Pfizer, Sanofi, and Eli Lilly and Company. Ultimately, a definitive acquisition offer culminated in a transaction led by Pfizer that reflected valuation trends seen in other deals such as Celgene acquisitions and reshaped shareholder outcomes involving institutional holders like State Street Corporation and Fidelity Investments.
Medivation navigated regulatory review processes with the Food and Drug Administration and compliance interactions with agencies such as the European Medicines Agency and national health authorities in Japan and Australia. The company managed patent portfolios prosecuted with firms experienced in IP matters involving competitors like Amgen and AbbVie and faced litigation practices similar to disputes seen with Merck and Bristol-Myers Squibb. Post-marketing safety surveillance involved pharmacovigilance reporting to bodies including FDA Adverse Event Reporting System and risk management planning aligned with guidance from World Health Organization experts and professional societies such as ASCO.
Medivation's development and commercialization of a novel androgen receptor inhibitor influenced subsequent drug discovery programs at institutions and companies including Astellas Pharma, Pfizer, Gilead Sciences, Novartis, and academic groups at Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. Its clinical trial designs, regulatory interactions with FDA and engagement with cooperative groups like SWOG and EORTC informed standards for endpoints and patient selection used by investigators at Mayo Clinic and Johns Hopkins University. The acquisition by Pfizer contributed to consolidation patterns observed with transactions involving Celgene, Allergan, and AbbVie, affecting venture capital strategies from firms such as Accel Partners and Kleiner Perkins and shaping career trajectories for executives who later joined organizations like Roche and AstraZeneca.
Category:Biotechnology companies Category:Pharmaceutical companies of the United States